Journal article icon

Journal article

HDAC inhibitor-based therapies and haematological malignancy.

Abstract:

Reversible acetylation mediated by histone deacetylase (HDAC) influences a broad repertoire of physiological processes, many of which are aberrantly controlled in tumour cells. Since HDAC inhibition prompts tumour cells to enter apoptosis, small-molecule HDAC inhibitors have been developed as a new class of mechanism-based anticancer agent, many of which have entered clinical trials. While the clinical picture is evolving and the precise utility of HDAC inhibitors remains to be determined, it...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1093/annonc/mdn792

Authors


Stimson, L More by this author
Fotheringham, S More by this author
La Thangue, NB More by this author
Journal:
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Volume:
20
Issue:
8
Pages:
1293-1302
Publication date:
2009-08-05
DOI:
EISSN:
1569-8041
ISSN:
0923-7534
URN:
uuid:d57bcd6a-e5e5-4d49-a984-cd922d702041
Source identifiers:
248163
Local pid:
pubs:248163

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP